• 1
    Theodore J, Starnes VA, Lewiston NJ. Obliterative bronchiolitis. Clin Chest Med 1990; 11: 30921.
  • 2
    Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart–lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 413; discussion 13–4.
  • 3
    Scott JP, Higenbottam TW, Sharples L et al. Risk factors for obliterative bronchiolitis in heart–lung transplant recipients. Transplantation 1991; 51: 8137.
  • 4
    Watschinger B. How T cells recognize alloantigen: evidence for two pathways of allorecognition. Nephrol Dial Transplant 1995; 10: 15568.
  • 5
    Chirmule N, Avots A, LakshmiTamma SM, Pahwa S, Serfling E. CD4-mediated signals induce T cell dysfunction in vivo. J Immunol 1999; 163: 6449.
  • 6
    Waldmann H, Cobbold S. Monoclonal antibodies for the induction of transplantation tolerance. Curr Opin Immunol 1993; 5: 7538.
  • 7
    Van Epps DE, Potter JW, Durant DA. Production of a human T lymphocyte chemotactic factor by T cell subpopulations. J Immunol 1983; 130: 272731.
  • 8
    Bellini A, Yoshimura H, Vittori E, Marini M, Mattoli S. Bronchial epithelial cells of patients with asthma release chemoattractant factors for T lymphocytes. J Allergy Clin Immunol 1993; 92: 41224.
  • 9
    Rand TH, Cruikshank WW, Center DM, Weller PF. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 1991; 173: 15218.
  • 10
    Center DM, Cruikshank W. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 1982; 128: 25638.
  • 11
    Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM. IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 1996; 168: 1006.
  • 12
    Cruikshank WW, Lim K, Theodore AC et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol 1996; 157: 52408.
  • 13
    Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 1996; 157: 195864.
  • 14
    Klimiuk PA, Goronzy JJ, Weyand CM. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 1999; 162 (7):42939.
  • 15
    Pinsonneault S, El Bassam S, Mazer B, Cruikshank WW, Laberge S. IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J Allergy Clin Immunol 2001; 107: 47782.
  • 16
    Laberge S, Ernst P, Ghaffar O et al. Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol 1997; 17: 193202.
  • 17
    Laan M, Qvarfordt I, Riise GC, Andersson BA, Larsson S, Linden A. Increased levels of interleukin-16 in the airways of tobacco smokers: relationship with peripheral blood T lymphocytes. Thorax 1999; 54: 9116.
  • 18
    Cruikshank WW, Long A, Tarpy RE et al. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995; 13: 73847.
  • 19
    Riise GC, Schersten H, Nilsson F, Ryd W, Andersson BA. Activation of eosinophils and fibroblasts assessed by eosinophil cationic protein and hyaluronan in BAL. Association with acute rejection in lung transplant recipients. Chest 1996; 110: 8996.
  • 20
    Riise GC, Kjellstrom C, Ryd W et al. Inflammatory cells and activation markers in BAL during acute rejection and infection in lung transplant recipients: a prospective, longitudinal study. Eur Respir J 1997; 10: 17426.
  • 21
    Yousem SA, Berry GJ, Brunt EM et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection − lung rejection study-group. J Heart Transplant 1990; 9: 593601.
  • 22
    Cooper JD, Billingham M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 7136.
  • 23
    Shimada M, Matsumata T, Taketomi A et al. The role of interleukin-6, interleukin-16, tumor necrosis factor-alpha and endotoxin in hepatic resection. Hepatogastroenterology 1995; 42: 6917.
  • 24
    Ross DJ, Yeh AY, Nathan SD et al. Differential soluble interleukin-2R levels in bilateral bronchoalveolar lavage after single lung transplantation. J Heart Lung Transplant 1994; 13: 9729.
  • 25
    Lai KN, Leung JC, Lai FM. Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T lymphocytes in vitro. Pathology 1991; 23: 2248.
  • 26
    Fujita T, Matsumoto Y, Hirai I et al. Immunosuppressive effect on T cell activation by interleukin-16-cDNA-transfected human squamous cell line. Cell Immunol 2000; 202: 5460.